Immunohistochemical Expression of HER2/neu and β-catenin in Urothelial Carcinoma: “A Dawn of Hope"
DOI:
https://doi.org/10.21276/apalm.3505Keywords:
Immunohistochemistry, Grade, Muscle invasive, TURBTAbstract
Background: Urothelial carcinoma is the 10th most commonly occurring and 13th most common cause of cancer-related deaths worldwide. The major prognostic factors in urothelial carcinomas are the depth of invasion into the bladder wall and the degree of differentiation of the tumour. However, there is no reliable prognostic marker, and thus molecular markers are required to estimate the individual prognosis of patients as well as for effective treatment.
Methods: To evaluate HER2/Neu and β-catenin immunohistochemical (IHC) expression in urothelial carcinoma and their correlation with tumour grade and stage, thus contributing as prognostic factors. Fifty formalin-fixed TURBT specimens of urinary bladder carcinoma were collected from our hospital during the period from January 2023-June 2024. Hematoxylin and Eosin stained sections were done, along with microscopical examination, and immunohistochemistry for HER2/Neu and 8-catenin were done. A p-value of <0.05 was considered statistically significant.
Results: A total of 38 (82%) out of 46 cases of high-grade urothelial carcinoma and 24 (92.3%) out of 26 cases of muscle-invasive urothelial carcinoma expressed strong HER2/Neu membranous positivity (score 3). HER2/Neu expression was found to be statistically significant with respect to histological grade and pathological stage (p< 0.001). 42/46 cases of high-grade urothelial carcinoma showed β-catenin positivity, and intensity increased with an increase in pathological stage (p<0.001).
Conclusion: A positive association between HER2/Neu and 3-catenin expression with tumour grade and pathological stage of urothelial carcinoma was found, contributing to prognostic assessment and thereby guiding targeted therapy.
References
1. Saginala K, Barsouk A, Aluru SJ. Epidemiology of bladder cancer. Med Sci. 2020;13:15.
2. Bray F, Colombet M. Mery L. Cancer Incidence in Five Continents. Vol. 11. Lyon: International Agency for Research on Cancer; 2017. Available from: https://www.publications.iarc.fr/databases/iarc-cancerbases/cancer-incidence-in-five-continents-Vol.-XI-2017. [Last accessed on 2020 Jun 03].
3. Rosai J. Rosai and Ackerman's surgical pathology. Elsevier Health Sciences; 2011.
4. Gandour-Edwards R, Lara PJ, Folkins AK. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer. 2002:95(5):1009-15.
5. Biswas RR, Mangal S, Guha D, Basu K. An epidemiological study of cases of urothelial carcinoma of urinary bladder in a tertiary care centre. J Krishna Inst Med Sci Univ. 2013:2:82-8.
6. Laishram RS, Kipgen P, Laishram S. Urothelial tumors of the urinary bladder in Manipur: A histopathological perspective. Asian Pac J Cancer Prev. 2012:13:2477-9.
7. Mishra V, Balasubramaniam G. Urinary bladder cancer and its associated factors: an epidemiological overview. Indian J Med Sci. 2021:73:239-48.
8. Holmäng S, Hedelin H, Anderström C. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J. Urol. 1995;153:1823-6; discussion: 1826-7.
9. Schuell B, Gruenberger T. Scheithauer W. HER 2/neu protein expression in colorectal cancer. BMC cancer. 2006;8(6):123.
10. Jimenez RE, Hussain M, Bianco FJ. Her-2/Neu overexpression in muscle-invasive Urothelial carcinoma of the bladder: Prognostic Significance and Comparative Analysis in Primary and Metastatic tumors. Clin Cancer Res. 2001;7(8):2440-7.
11. Hudis CA. Trastuzumab: Mechanism of action and use in clinical practice. N. Engl. J. Med. 2007;357:39-51.
12. Takayama T. Shiozaki H, Shibamoto S. Beta-catenin expression in human cancers. Am J Pathol. 1996:148:39-46.
13. Shimazui T, Schalken JA, Giroldi LA. Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res. 1996;56:4154-8.
14. Osterheld MC, Bian YS, Bosman FT, et al. Beta-catenin expression and its association with prognostic factors in adenocarcinoma developed in Barrett esophagus. Am J Clin Pathol. 2002;117:451-6.
15. Urakami S, Shiina H, Enokida H. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res. 2006;12:383-91.
16. Kastritis E, Murray S, Kyriakou F. Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication. Int J Cancer. 2009;124:103-8.
17. Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
18. Guntimadugu Madhulatha, Muram Reddy Vijaya Lakshmi, Kharidehal Durga. Expression of Her2/neu in Urothelial Neoplasms and its Association with Histopathological Prognostic Parameters. Journal of Research in Applied and Basic Medical Sciences. 2023:9(1):11-23.
19. Hu X, Ruan Y, Cheng F, Yu W, Zhang X, Larré S. p130Cas, E-cadherin and -catenin in human transitional cell carcinoma of the bladder: expression and clinicopathological significance. Int J Urol. 2011;18(9):630-7.
20. Badawia B Ibrahim, Samira A Mahmoud, Alzahraa A Mohamed. Expression of HER2/neu and Ki-67 in Urothelial Carcinoma and their Relation to Clinicopathological Data: An Egyptian Study. Journal of Clinical and Diagnostic Research. 2021 Mar 15(3):EC06-EC09.
21. Zeb MA, Nadeem MS, Saeed AS. Noninvasive treatment of muscle invasive bladder cancer in patients with deranged renal profile. Pakistan Armed Forces Medical Journal. 2018;68(6):1636-41.
22. Noora Ali Jawad, Dr. Hussam Hasson Ali, Mohammed Subhi Kamal. A study on Her2/Neu and Ki-67 Immunohistochemical Expression in Transitional Cell Carcinoma of the Urinary Bladder (A Clinicopathological Study). IOSR Journal of Dental and Medical Sciences (IOSR-JDMS). 2016 Feb;15(2 Ver. III):06-12.
23. Sukhmani Samra, Sarita Nibhoria, Vaneet Kaur Sandhu. Evaluation of the immunohistochemical expression of HER2/NEU in urinary bladder neoplasms in a tertiary care hospital. Int J Res Med Sci. 2023 May: 11(5):1687-1692.
24. Ahmed I. Elsayed, Ph.D., M. S. A. S. M., R. MATAR, M.D., E. Immunohistochemical Expression of HER2/NEU and CD10 in Urothelial Carcinoma of Urinary Bladder. The Medical Journal of Cairo University. 2021;89(December):2533-2541.
25. Muhammad Kashif Sarfraz, Umbereen Anwar, Ameer Alam. A study on Expression of HER2/NEU in Different Grades of Urothelial Carcinoma of Urinary Bladder. PJMHS. 2019 Oct-Dec 13(4).
26. Haque S, Dewan RK, Saleh SA. Histomorphological Study of Urinary Bladder Tumor and Status of HER2/Neu and Ki67 Expression in Urothelial Carcinoma. Journal of Histopathology And Cytopathology. 2018 Jul;2(2):99-108.
27. Kumar S, Prajapati O, Vaiphei K, Parmar KM, Sriharsha AS, Singh SK, et al. Human epidermal growth factor receptor 2/neu overexpression in urothelial carcinoma of the bladder and its prognostic significance: Is it worth hype? South Asian J Cancer. 2015:4:115-7.
28. Muhammad Sanusi Haruna, Akinfenwa Taoheed Atanda, Yawale Iliyasua. Study on Pattern of HER2 Overexpression in Urinary Bladder Carcinomas in Kano, Nigeria. Ann Afr Surg. 2023;20(1):7-13.
29. Mahak Agarwal, Milan Jaiswal, Surabhi Pandey, et al. Her2neu expression in urinary bladder cancer: Histopathological, clinico-radiological and epidemiological aspects. Indian Journal of Pathology and Oncology. 2019 Jul-Sep;6(3):489-496.
30. Samane Danaei. Survey on Her2/neu Expression and Its Correlation with Some Pathological Factors in Urothelial Bladder Tumors. Iran Red Crescent Med J. 2018 Feb 20(2):e58494.
31. Maurya N, Singh R, Goel A, et al. Clinicohistopathological implications of phosphoserine 9 glycogen synthase kinase-3/-catenin in urinary bladder cancer patients. World J Clin Oncol. 2019;10(4):166-182.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Falaq Rahim, Shubham Bhattacharya, Mohit Kumar Dutta, Chhanda Das, Ayan Saha
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
